AstraZeneca drug reduces COPD flare ups in late-stage trials

Group 1 - AstraZeneca's experimental treatment tozorakimab has successfully met the main goal in two late-stage trials [1] - The treatment demonstrated a significant reduction in flare-ups of chronic obstructive pulmonary disease (COPD), commonly referred to as "smoker's lung" [1]